Talaris Therapeutics, Inc. - FORM S-1 - EX-23.1 - April 16, 2021

Attached files

file filename
S-1 - S-1 - Talaris Therapeutics, Inc.d51356ds1.htm
EX-10.15 - EX-10.15 - Talaris Therapeutics, Inc.d51356dex1015.htm
EX-10.14 - EX-10.14 - Talaris Therapeutics, Inc.d51356dex1014.htm
EX-10.13 - EX-10.13 - Talaris Therapeutics, Inc.d51356dex1013.htm
EX-10.12 - EX-10.12 - Talaris Therapeutics, Inc.d51356dex1012.htm
EX-10.11 - EX-10.11 - Talaris Therapeutics, Inc.d51356dex1011.htm
EX-10.10 - EX-10.10 - Talaris Therapeutics, Inc.d51356dex1010.htm
EX-10.9 - EX-10.9 - Talaris Therapeutics, Inc.d51356dex109.htm
EX-10.8 - EX-10.8 - Talaris Therapeutics, Inc.d51356dex108.htm
EX-10.6 - EX-10.6 - Talaris Therapeutics, Inc.d51356dex106.htm
EX-10.5 - EX-10.5 - Talaris Therapeutics, Inc.d51356dex105.htm
EX-10.1 - EX-10.1 - Talaris Therapeutics, Inc.d51356dex101.htm
EX-4.2 - EX-4.2 - Talaris Therapeutics, Inc.d51356dex42.htm
EX-4.1 - EX-4.1 - Talaris Therapeutics, Inc.d51356dex41.htm
EX-3.3 - EX-3.3 - Talaris Therapeutics, Inc.d51356dex33.htm
EX-3.1 - EX-3.1 - Talaris Therapeutics, Inc.d51356dex31.htm

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the use in this Registration Statement on Form S-1 of our report dated February 26, 2021, relating to the financial statements of Talaris Therapeutics, Inc. We also consent to the reference to us under the heading “Experts” in such Registration Statement.

/s/Deloitte & Touche LLP

Boston, Massachusetts

April 16, 2021